

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

JUNE 2025



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: **RECCE® 327** as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; **RECCE® 435** as an orally-administered therapy for bacterial infections; and **RECCE® 529** for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria - the challenge of all existing antibiotics to date.

Sepsis affects **50 million people worldwide** a year. There are currently **no drug therapies** specifically for the treatment of severe sepsis and it is by far the **most expensive condition** treated in US hospitals.

The FDA has awarded RECCE® 327 **Qualified Infectious Disease Product** designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has also been included on **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.**

Recce wholly owns its automated manufacturing, ready to support human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent
- World's Most Clinically Advanced New Class of Anti-Infectives** focussed upon the urgent global health threat of antibiotic-resistant superbugs
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, ABSSSIs, Diabetic Foot Infections and more**
- R327 bactericidal activity against all six ESKAPE pathogens
- Unique Mechanism of Action - R327 does not succumb to antimicrobial mutation (superbugs) - fundamental challenge of all existing antibiotics to date. It works fast and keeps on working with repeated use
- R327 cleared for use under Therapeutic Goods Administration (TGA) Special Access Scheme - Category A
- R327 included in **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens**, recognising Recce's efforts to combat antimicrobial resistance.
- Clinical Phase I-II and preclinical product produced at RECCE Macquarie Park facility in Australia. GMP Manufacturing facility in Australia for Phase III/Scale up
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433) Advanced Overseas Finding*** across RCE infectious disease portfolio*

SNAP SHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	AUD \$0.2750 - A\$0.6200
Market Cap	AUD \$80m (priced at \$0.3250)
Cash balance*	A\$16m
Shares on issue	262m
3 month avg. vol	224.74K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

*The Company has raised a total of approximately A\$8.4 million through existing shareholders and now goes to the wider market for the remainder A\$7.4m which it expects to place at the same price in near weeks.

Recce expects a pro-forma cash position post the Offer of -A\$16.0 million (before offer costs).

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced - Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced - Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - **Granted**

Unique and highly economical manufacturing process

Patent Family 2 - **Pending/Granted**

Applications (Multi-drug delivery)

Patent Family 3 - **Granted**

Anti-viral use

Patent Family 4 - **Pending/Granted**

Process for Preparation of Biologically Active Copolymer (**Australia Granted**, other Patent Cooperation Treaty countries **pending/allowed**)

Efficacy - RECCE® 327

- 99.9% effective against full suite of ESKAPE pathogens including Multidrug-Resistant forms
- Acts against bacteria in both normal and mutated superbug forms
- Multiple tests demonstrate efficacy against Gram-positive and Gram-negative including their superbug forms
- *In-vitro* studies of RECCE® 327 demonstrate a faster kill rate than existing antibiotics
- Contains a patented polymeric structure, intentionally designed to overcome the traditional challenges of bacterial mutation/resistance
- *In-vivo* studies against SARS-CoV-2 (COVID-19) and influenza virus

Safety - RECCE® 327


- Data review showed both methods of administration, I.V. and Gel, of multiple RECCE®327 clinical trials **to be safe & well tolerated - no serious adverse events**
- Multiple studies of mutagenicity (cancer) are clear
- Numerous studies to date indicate the safety of RECCE® 327
- Is suited to administration against sepsis by intravenous drip
- Indicates a safe therapeutic dosing window over multiple time stamps

RECCE® 327 Mechanism of Action




Stage 1

R327 targets and irreversibly bind to essential bacterial proteins



Stage 2

R327 disrupts bacterial metabolism and depletes ATP at the cell surface



Stage 3


R327 kills bacteria rapidly without inducing cell lysis



Stage 4

R327 is rapidly and irreversibly bactericidal

RECCE® Multiple Anti-Infective Applications



World Health Organisation (WHO) List of Most Threatening Antibiotic-Resistant Bacteria

The WHO published a priority list of 12 antibiotic-resistant bacteria*.

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- 1 Active *in vitro* against Recce's own superbug of this bacterium
 - 2 Active *in vivo* against a member of this family CRE *E. coli*
 - 3 Active *in vitro* and against superbug variant CRAB
 - 4 Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - 5 Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - 6 Active *in vitro* (superbug not available)
 - 7 Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - 8 Active *in-vitro* against *Streptococcus pyogenes*
 - 9 Active *in-vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

SEPTEMBER 2024



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: **RECCE® 327** as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; **RECCE® 435** as an orally-administered therapy for bacterial infections; and **RECCE® 529** for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria – the challenge of all existing antibiotics to date.

Sepsis affects **50 million people worldwide** a year. There are currently **no drug therapies** specifically for the treatment of severe sepsis and it is by far the **most expensive condition** treated in US hospitals.

The FDA has awarded RECCE® 327 **Qualified Infectious Disease Product** designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has also been included on **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.**

Recce wholly owns its automated manufacturing, ready to support human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent
- World's Most Clinically Advanced New Class of Anti-Infectives** focussed upon the urgent global health threat of antibiotic-resistant superbugs
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, Diabetic Foot Infections and more**
- R327 bactericidal activity against all six ESKAPE pathogens
- Unique Mechanism of Action – R327 does not succumb to antimicrobial mutation (superbugs) - fundamental challenge of all existing antibiotics to date. It works fast and keeps on working with repeated use
- R327 cleared for use under Therapeutic Goods Administration (TGA) Special Access Scheme - Category A
- R327 included in **The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.** The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance.
- Manufacturing Established – quality and quantity suitable for all clinical trial phases (highly economic & scalable)
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433)** Advanced Overseas Finding* across RCE infectious disease portfolio*

*The Advanced Finding is a binding, underwritten guarantee provided by the Australian Government, which affirms the Company's R&D activities are of national interest and extends the 43.5% R&D rebate from locally, to cover those undertaken by the Company anywhere in the world for a period of three years. This finding does not constitute a grant, or an upfront payment of the amount awarded

SNAP SHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	USD \$0.2742 – U\$0.4682
Market Cap	USD \$78.241m (priced at \$0.33)
Cash balance	USD \$13.3m*
Shares on issue	231.61m
3 month avg. vol	201.04K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

*Successful completion of an institutional and SPP placement raised A\$12.4m, giving Recce a pro-forma cash balance of approximately A\$19.8 million.

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced – Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced – Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 – Granted

Unique and highly economical manufacturing process

Patent Family 2 – Pending/Granted

Applications (Multi-drug delivery)

Patent Family 3 – Granted

Anti-viral use

Patent Family 4 – Pending/Granted

Process for Preparation of Biologically Active Copolymer (Australia Granted, other Patent Cooperation Treaty countries pending/allowed)

Efficacy - RECCE® 327

- 99.9% effective against full suite of ESKAPE pathogens including Multidrug-Resistant forms
- Acts against bacteria in both normal and mutated superbug forms
- Multiple tests demonstrate efficacy against Gram-positive and Gram-negative including their superbug forms
- *In-vitro* studies of RECCE® 327 demonstrate a faster kill rate than existing antibiotics
- Contains a patented polymeric structure, intentionally designed to overcome the traditional challenges of bacterial mutation/resistance
- *In-vivo* studies against SARS-CoV-2 (COVID-19) and influenza virus

Safety - RECCE® 327


- Multiple studies of toxicity in small and large animals
- Multiple studies of mutagenicity (cancer) are clear
- Numerous studies to date indicate the safety of RECCE® 327
- Is suited to administration against sepsis by intravenous drip
- Indicates a safe therapeutic dosing window over a 1-hour infusion
- Data review of Phase I (I.V.) clinical trial of R327 in 80 human subjects, achieved all study end-points and **showed RECCE®327 to be safe & well tolerated - no serious adverse events noted**

RECCE® 327 Mechanism of Action




Stage 1

R327 permeabilises cell membrane and enters the cell



Stage 2

R327 interrupts bacterial cellular energetics via ATP Synthesis



Stage 3


Cellular division & non-dividing cell functions are disrupted



Stage 4

R327 is rapidly and irreversibly bactericidal

RECCE® Multiple Anti-Infective Applications



*Including post-operative infection, wound infections and diabetic foot infections

** The US Department of Defence has Recommended R327 Gel (R327G) as a topical treatment for Burn Wound Infections for grant funding of USD \$2.0 million (AUD 3.0 million).

World Health Organisation (WHO) List of Most Threatening Antibiotic-Resistant Bacteria

The WHO published a priority list of 12 antibiotic-resistant bacteria*.

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- 1 Active *in vitro* against Recce's own superbug of this bacterium
 - 2 Active *in vivo* against a member of this family CRE *E. coli*
 - 3 Active *in vitro* and against superbug variant CRAB
 - 4 Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - 5 Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - 6 Active *in vitro* (superbug not available)
 - 7 Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - 8 Active *in-vitro* against *Streptococcus pyogenes*
 - 9 Active *in-vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024



Sydney – Head Office

Level 23, 180 George St
Salesforce Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

OCTOBER 2024



新世代の抗感染症薬における新興のグローバルリーダー

レッセ・ファーマシューティカルズ株式会社 (ASX: RCE, FSE: R9Q) は、オーストラリアに拠点を置く臨床段階のバイオテクノロジー企業で、抗生物質耐性のスーパーバグという差し迫った世界的な健康問題に対処するために設計された新しい合成抗感染症薬の開発と商業化に従事しています。

レッセの抗感染症薬パイプラインには、3つの特許取得済みの広域スペクトル合成ポリマー抗感染症薬が含まれています。

- RECCE® 327 は、グラム陽性菌およびグラム陰性菌、さらにはそれらのスーパーバグ形態による深刻かつ生命を脅かす可能性のある感染症の治療を目的とした静脈内および外用療法として開発されています。
- RECCE® 435 は、経口投与される細菌感染症治療薬です。
- RECCE® 529 は、ウイルス感染症治療薬です。

これらの多層的な作用機序を通じて、レッセの抗感染症薬は、これまでの抗生物質が直面していた課題である細菌の過剰な細胞変異を克服する可能性を持っています。

敗血症は、世界で年間5000万人が影響を受けており、現在、重度の敗血症治療に特化した薬物療法は存在していません。また、米国の病院で治療される中で最も高額な疾患でもあります。

FDA (米国食品医薬品局) は、RECCE® 327 に「感染症指定製品 (Qualified Infectious Disease Product)」の指定を与え、GAIN法 (Generating Antibiotic Initiatives Now) の下で「ファストトラック指定」と10年間の市場独占権を承認後に付与しました。さらに、この指定に加えて、RECCE® 327はThe Pew Charitable Trustsの「開発中の新しい抗生物質グローバルパイプライン」に唯一の合成ポリマーおよび敗血症治療薬候補として含まれています。

レッセは自動化された製造プロセスを完全に所有しており、ヒト臨床試験を支援する準備が整っています。レッセの抗感染症薬パイプラインは、未解決の医療ニーズに応えるために、RECCE®技術の独自の機能を活用することを目指しています。

会社概要

- 特許によって保護された、細菌およびウイルスに対する新しいクラスの独自の抗感染症薬
- 抗生物質耐性スーパーバグという差し迫った世界的健康脅威に焦点を当てた、世界で最も臨床的に進んだ新しいクラスの抗感染症薬
- 複数の臨床試験が完了し、他の試験も進行中 - 敗血症/尿路敗血症、熱傷感染症、糖尿病性足潰瘍などの大きな未解決の医療ニーズに対応する広範な治療の可能性
- R327は、すべてのESKAPE病原体に対する殺菌活性を持つ
- 独自の作用機序 - R327は抗菌変異 (スーパーバグ) に屈せず、既存のすべての抗生物質が直面してきた根本的な課題に対処。速効性があり、繰り返し使用しても効果を維持
- R327は、治療薬品局 (TGA) の特別アクセススキームカテゴリAで使用が承認
- R327は、開発中の唯一の合成ポリマーおよび敗血症薬候補として、ピュー慈善信託グローバル新抗生物質開発パイプラインに含まれています。世界保健機関 (WHO) は、優先病原体に対する臨床開発中の抗菌製品リストにR327、R435、およびR529を追加し、抗菌薬耐性と戦うRecceの取り組みを評価
- 製造が確立され、すべての臨床試験フェーズに適した品質と数量を提供 (経済的かつ拡張可能)
- オーストラリア政府は、RCE感染症ポートフォリオ全体にわたり、5,494万7,284豪ドル (3,704万3,433米ドル) の海外研究費を認定

「高度な認定」は、オーストラリア政府によって提供される法的拘束力のある保証であり、同社の研究開発活動が国家的利益に該当することを確認し、国内での43.5%の研究開発リベートを、同社が世界のどこで行った研究にも適用するものです。この適用期間は3年間です。この認定は、助成金や認定額の前払いを意味するものではありません。

スナップショット

ティッカー	ASX:RCE, FSE:R9Q
掲載日	2016年1月、2021年3月
「上場日」	AUD \$0.4100 - A\$0.6950
時価総額	AUD \$118.718m (priced at \$0.5120)
現金残高	A\$19.8m*
発行済み株式数	231.87m
3か月平均変動率	199.53K (per trading day)
セクタ	Pharmaceuticals, Biotechnology & Life Sciences

*機関投資家向けとSPP (株式購入計画) による増資が成功し、1,240万豪ドルを調達し、Recceのプロフォーム現金残高は約1,980万豪ドルとなりました。

取締役会と経営陣

Dr John Prendergast	会長
James Graham	マネージングディレクター兼最高経営責任者 (CEO)
Michele Dilizia	取締役兼最高科学責任者 (CSO)
Dr Justin Ward	取締役兼主任品質化学者
Dr Alan W Dunton	チーフメディカルアドバイザー兼社外取締役
Alistair McKeough	社外取締役
Arthur Kollaras	製造部長
Justin Reynolds	最高財務責任者 (CFO) (外部委託-Pitcher Partners)
Maggie Niewidok	会社秘書 (外部委託-Kardos Scanlan)

特許ポートフォリオ

製造プロセスをカバーする特許は2029年まで有効です。追加の投与方法や抗ウイルス用途をカバーする暫定特許は2037年まで有効です。

Recce Pharmaceuticals Ltd の特許ポートフォリオは、アメリカ、ヨーロッパ、日本、中国、オーストラリアといった主要な製薬市場で特許が付与され、さらに強化されています。

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - Granted
「独自で非常に経済的な製造プロセス」

Patent Family 2 - Pending/Granted
「適用例 (多剤送達)」

Patent Family 3 - Granted
「抗ウイルス用途」

Patent Family 4 - Pending/Granted
「生物活性コポリマーの調製プロセス (オーストラリアで承認済み、他の特許協力条約締結国では審査中または承認済み)」

「有効性 - RECCE® 327」

- ESKAPE病原体全体に対して99.9%の効果があり、多剤耐性型も含まれます
- 通常および変異したスーパーバグ形態の細菌に対して効果を発揮します
- 複数のテストで、グラム陽性菌およびグラム陰性菌、さらにそのスーパーバグ形態に対する有効性が実証されています
- RECCE® 327のin vitro (試験管内) 研究では、既存の抗生物質よりも速い殺菌速度が示されています
- 特許取得済みのポリマー構造を含み、細菌の変異や耐性に対する従来の課題を克服するよう意図的に設計されています
- SARS-CoV-2 (COVID-19) およびインフルエンザウイルスに対するin vivo (生体内) 研究

安全性 - RECCE® 327


- 小動物および大型動物での複数の毒性試験
- 発がん性(突然変異原性)に関する複数の研究で明確な結果
- これまでの多数の研究でRECCE® 327の安全性が示されています
- 敗血症の治療に静脈内点滴で投与するのに適しています
- 1時間の点滴中に安全な治療用投与範囲を示しています
- RECCE® 327の第I相(静脈内投与)臨床試験(80名の被験者)におけるデータレビューでは、すべての研究エンドポイントを達成し、RECCE® 327が安全で耐容性が高いことが示されました - 重篤な有害事象は確認されませんでした

RECCE® 327 の作用機序




ステージ 1

R327 は細胞膜を透過し、細胞内に侵入します



ステージ 2

R327 は ATP 合成を介して細菌の細胞エネルギー代謝を阻害します



ステージ 3

細胞分裂および非分裂細胞の機能が阻害されます



ステージ 4

R327 は迅速かつ不可逆的に殺菌効果を発揮します


世界保健機関 (WHO) の最も脅威となる抗生物質耐性菌のリスト。

WHOは12種類の抗生物質耐性菌の優先リストを発表しました。

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- Active *in vitro* against Recce's own superbug of this bacterium
 - Active *in vivo* against a member of this family CRE *E. coli*
 - Active *in vitro* and against superbug variant CRAB
 - Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - Active *in vitro* (superbug not available)
 - Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - Active *in-vitro* against *Streptococcus pyogenes*
 - Active *in-vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024

RECCE® Multiple Anti-Infective Applications



*Including post-operative infection, wound infections and diabetic foot infections

** The US Department of Defence has Recommended R327 Gel (R327G) as a topical treatment for Burn Wound Infections for grant funding of USD \$2.0 million (AUD 3.0 million).



Sydney – Head Office

Level 23, 180 George St
Salesforce Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

OCTOBER 2024



新世代の抗感染症薬における新興のグローバルリーダー

レッセ・ファーマシューティカルズ株式会社 (ASX: RCE, FSE: R9Q) は、オーストラリアに拠点を置く臨床段階のバイオテクノロジー企業で、抗生物質耐性のスーパーバグという差し迫った世界的な健康問題に対処するために設計された新しい合成抗感染症薬の開発と商業化に従事しています。

レッセの抗感染症薬パイプラインには、3つの特許取得済みの広域スペクトル合成ポリマー抗感染症薬が含まれています。

- RECCE® 327 は、グラム陽性菌およびグラム陰性菌、さらにはそれらのスーパーバグ形態による深刻かつ生命を脅かす可能性のある感染症の治療を目的とした静脈内および外用療法として開発されています。
- RECCE® 435 は、経口投与される細菌感染症治療薬です。
- RECCE® 529 は、ウイルス感染症治療薬です。

これらの多層的な作用機序を通じて、レッセの抗感染症薬は、これまでの抗生物質が直面していた課題である細菌の過剰な細胞変異を克服する可能性を持っています。

敗血症は、世界で年間5000万人が影響を受けており、現在、重度の敗血症治療に特化した薬物療法は存在していません。また、米国の病院で治療される中で最も高額な疾患でもあります。

FDA (米国食品医薬品局) は、RECCE® 327 に「感染症指定製品 (Qualified Infectious Disease Product)」の指定を与え、GAIN法 (Generating Antibiotic Initiatives Now) の下で「ファストトラック指定」と10年間の市場独占権を承認後に付与しました。さらに、この指定に加えて、RECCE® 327はThe Pew Charitable Trustsの「開発中の新しい抗生物質グローバルパイプライン」に唯一の合成ポリマーおよび敗血症治療薬候補として含まれています。

レッセは自動化された製造プロセスを完全に所有しており、ヒト臨床試験を支援する準備が整っています。レッセの抗感染症薬パイプラインは、未解決の医療ニーズに応えるために、RECCE®技術の独自の機能を活用することを目指しています。

会社概要

- 特許によって保護された、細菌およびウイルスに対する新しいクラスの独自の抗感染症薬
- 抗生物質耐性スーパーバグという差し迫った世界的健康脅威に焦点を当てた、世界で最も臨床的に進んだ新しいクラスの抗感染症薬
- 複数の臨床試験が完了し、他の試験も進行中 - 敗血症/尿路敗血症、熱傷感染症、糖尿病性足潰瘍などの大きな未解決の医療ニーズに対応する広範な治療の可能性
- R327は、すべてのESKAPE病原体に対する殺菌活性を持つ
- 独自の作用機序 - R327は抗菌変異 (スーパーバグ) に屈せず、既存のすべての抗生物質が直面してきた根本的な課題に対処。速効性があり、繰り返し使用しても効果を維持
- R327は、治療薬品局 (TGA) の特別アクセススキームカテゴリAで使用が承認
- R327は、開発中の唯一の合成ポリマーおよび敗血症薬候補として、ピュー慈善信託グローバル新抗生物質開発パイプラインに含まれています。世界保健機関 (WHO) は、優先病原体に対する臨床開発中の抗菌製品リストにR327、R435、およびR529を追加し、抗菌薬耐性と戦うRecceの取り組みを評価
- 製造が確立され、すべての臨床試験フェーズに適した品質と数量を提供 (経済的かつ拡張可能)
- オーストラリア政府は、RCE感染症ポートフォリオ全体にわたり、5,494万7,284豪ドル (3,704万3,433米ドル) の海外研究費を認定

「高度な認定」は、オーストラリア政府によって提供される法的拘束力のある保証であり、同社の研究開発活動が国家的利益に該当することを確認し、国内での43.5%の研究開発リポートを、同社が世界のどこで行った研究にも適用するものです。この適用期間は3年間です。この認定は、助成金や認定額の前払いを意味するものではありません。

スナップショット

ティッカー	ASX:RCE, FSE:R9Q
掲載日	2016年1月、2021年3月
「上場日」	AUD \$0.4100 - A\$0.6950
時価総額	AUD \$118.718m (priced at \$0.5120)
現金残高	A\$19.8m*
発行済み株式数	231.87m
3か月平均変動率	199.53K (per trading day)
セクタ	Pharmaceuticals, Biotechnology & Life Sciences

*機関投資家向けとSPP (株式購入計画) による増資が成功し、1,240万豪ドルを調達し、Recceのプロフォーム現金残高は約1,980万豪ドルとなりました。

取締役会と経営陣

Dr John Prendergast	会長
James Graham	マネージングディレクター兼最高経営責任者 (CEO)
Michele Dilizia	取締役兼最高科学責任者 (CSO)
Dr Justin Ward	取締役兼主任品質化学者
Dr Alan W Dunton	チーフメディカルアドバイザー兼社外取締役
Alistair McKeough	社外取締役
Arthur Kollaras	製造部長
Justin Reynolds	最高財務責任者 (CFO) (外部委託-Pitcher Partners)
Maggie Niewidok	会社秘書 (外部委託-Kardos Scanlan)

特許ポートフォリオ

製造プロセスをカバーする特許は2029年まで有効です。追加の投与方法や抗ウイルス用途をカバーする暫定特許は2037年まで有効です。

Recce Pharmaceuticals Ltd の特許ポートフォリオは、アメリカ、ヨーロッパ、日本、中国、オーストラリアといった主要な製薬市場で特許が付与され、さらに強化されています。

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - Granted

「独自で非常に経済的な製造プロセス」

Patent Family 2 - Pending/Granted

「適用例 (多剤送達)」

Patent Family 3 - Granted

「抗ウイルス用途」

Patent Family 4 - Pending/Granted

「生物活性コポリマーの調製プロセス (オーストラリアで承認済み、他の特許協力条約締結国では審査中または承認済み)」

「有効性 - RECCE® 327」

- ESKAPE病原体全体に対して99.9%の効果があり、多剤耐性型も含まれます
- 通常および変異したスーパーバグ形態の細菌に対して効果を発揮します
- 複数のテストで、グラム陽性菌およびグラム陰性菌、さらにそのスーパーバグ形態に対する有効性が実証されています
- RECCE® 327のin vitro (試験管内) 研究では、既存の抗生物質よりも速い殺菌速度が示されています
- 特許取得済みのポリマー構造を含み、細菌の変異や耐性に対する従来の課題を克服するよう意図的に設計されています
- SARS-CoV-2 (COVID-19) およびインフルエンザウイルスに対するin vivo (生体内) 研究

安全性 - RECCE® 327


- 小動物および大型動物での複数の毒性試験
- 発がん性(突然変異原性)に関する複数の研究で明確な結果
- これまでの多数の研究でRECCE® 327の安全性が示されています
- 敗血症の治療に静脈内点滴で投与するのに適しています
- 1時間の点滴中に安全な治療用投与範囲を示しています
- RECCE® 327の第I相(静脈内投与)臨床試験(80名の被験者)におけるデータレビューでは、すべての研究エンドポイントを達成し、RECCE® 327が安全で耐容性が高いことが示されました - 重篤な有害事象は確認されませんでした

RECCE® 327 の作用機序




ステージ 1

R327 は細胞膜を透過し、細胞内に侵入します



ステージ 2

R327 は ATP 合成を介して細菌の細胞エネルギー代謝を阻害します



ステージ 3

細胞分裂および非分裂細胞の機能が阻害されます



ステージ 4

R327 は迅速かつ不可逆的に殺菌効果を発揮します


世界保健機関 (WHO) の最も脅威となる抗生物質耐性菌のリスト。

WHOは12種類の抗生物質耐性菌の優先リストを発表しました。

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- Active *in vitro* against Recce's own superbug of this bacterium
 - Active *in vivo* against a member of this family CRE *E. coli*
 - Active *in vitro* and against superbug variant CRAB
 - Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - Active *in vitro* (superbug not available)
 - Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - Active *in vitro* against *Streptococcus pyogenes*
 - Active *in vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024

RECCE® Multiple Anti-Infective Applications



*Including post-operative infection, wound infections and diabetic foot infections

** The US Department of Defence has Recommended R327 Gel (R327G) as a topical treatment for Burn Wound Infections for grant funding of USD \$2.0 million (AUD 3.0 million).



Sydney – Head Office

Level 23, 180 George St
Salesforce Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)

FEBRUARY 2026



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of a new class of **Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.**

Recce's lead candidate, RECCE® 327 (R327), is a patented, **broad-spectrum synthetic anti-infective being developed in multiple formulations, including intravenous and topical.** It is designed to treat serious bacterial infections, including those caused by drug-resistant **Gram-positive** and **Gram-negative** pathogens.

R327 as a Topical Gel (R327G) is currently advancing through **late-stage clinical development**, with a particular focus on addressing **diabetic foot infections (DFIs)**, a major complication of diabetes and a significant global health burden. Recce is also advancing a broader portfolio of synthetic anti-infectives targeting a range of unmet medical needs across bacterial and viral infections.

The Company's lead program is a Registrational Phase 3 trial of R327G for DFIs in Indonesia, with patient dosing now underway at five sites. The trial is designed to generate pivotal safety and efficacy data and serves as a potential gateway to broader regulatory and commercial opportunities across the ASEAN market.

The Company also has a Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established *in vitro* models targeting burn wound infections.

Recce's **fully owned, automated manufacturing facility** in Australia supports ongoing clinical development and scale-up. With a **strong global patent portfolio** and a **targeted focus on unmet medical needs in diabetic wound care**, Recce is **advancing a next-generation anti-infective platform poised for near-term commercialisation and global expansion.**

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent.
- **World's Most Clinically Advanced New Class of Anti-Infectives focussed upon the urgent global health threat of antibiotic-resistant superbugs.**
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, ABSSSIs, Diabetic Foot Infections and more**
- R327 bactericidal activity against all ESKAPEE pathogens.
- R327 cleared for use under **Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) - Category A**
- **Global recognition by the World Health Organization - inclusion underscores significance of R327** in combating AMR. **R327 uniquely classified as an adenosine triphosphate (ATP) production disruptor**, the only compound under this category **development for priority pathogens**, recognising Recce's efforts to combat antimicrobial resistance.
- **R327 has been awarded Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA under the GAIN Act, providing Fast Track status and 10 years of market exclusivity post-approval.**
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433) Advanced Overseas Finding*** across RCE infectious disease portfolio*

SNAPSHOT

Ticker	ASX:RCE, FSE:R9Q
Date listed	January 2016, March 2021
52 week range	AUD \$0.2750 - A\$0.7300
Market Cap	AUD \$179.40m (priced at \$0.6100)
Shares on issue	289.18m
3 month avg. vol	139.78K (per trading day)
Sector	Pharmaceuticals, Biotechnology & Life Sciences

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced - Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced - Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - **Granted**

Unique and highly economical manufacturing process

Patent Family 2 - **Pending/Granted**

Applications (Multi-drug delivery)

Patent Family 3 - **Granted**

Anti-viral use


Patent Family 4 - **Pending/Granted**

Process for Preparation of Biologically Active Copolymer


Australia, Israel, Canada, Japan, China and Hong Kong - Granted

Other Patent Cooperation Treaty - **pending/allowed**

RECCE® 327 Mechanism of Action



RECCE® Multiple Anti-Infective Applications



Efficacy - RECCE® 327

- Achieved a 93% positive clinical response in diabetic foot infection (DFI) patients during Phase II trials, with **no serious adverse events reported**
- Multiple SAS Category A patient cases in Australia have shown **rapid clinical improvement with RECCE® 327 Topical Gel**, including the avoidance of surgical intervention in severe infections
- In SAS Category A use, R327 demonstrated visible reductions in swelling, redness, and infection progression within 24–72 hours of a single application
- Maintains potency across both Gram-positive and Gram-negative bacteria, including their drug-resistant variants**
- Time-kill studies show RECCE® 327 acts faster than conventional antibiotics, rapidly depleting bacterial ATP and causing irreversible bacterial death
- Demonstrated 99.9% *in vitro* efficacy against the full suite of ESKAPEE pathogens**

Safety - RECCE® 327

- R327 has been shown to be safe and well tolerated across multiple Phase I and II clinical trials and/or SAS Category A patient cases – as either intravenous or topical gel**
- Phase I trials demonstrated intravenous **safety profile even at high doses up to 6,000 mg** delivered over a one-hour infusion
- No clinically significant changes were observed in laboratory tests, EKGs, telemetry, or vital signs, supporting systemic safety
- R327 displayed a clear therapeutic window across multiple dosing schedules and concentrations
- Topical application has shown to be non-irritating and well tolerated, even in infected, open wound sites**
- Multiple R327 studies of mutagenicity (cancer) are clear**



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

Efficacy - RECCE® 327

- 99.9% effective against full suite of ESKAPE pathogens including Multidrug-Resistant forms
- Acts against bacteria in both normal and mutated superbug forms
- Multiple tests demonstrate efficacy against Gram-positive and Gram-negative including their superbug forms
- *In-vitro* studies of RECCE® 327 demonstrate a faster kill rate than existing antibiotics
- Contains a patented polymeric structure, intentionally designed to overcome the traditional challenges of bacterial mutation/resistance
- *In-vivo* studies against SARS-CoV-2 (COVID-19) and influenza virus

Safety - RECCE® 327


- Data review showed both methods of administration, I.V. and Gel, of multiple RECCE®327 clinical trials **to be safe & well tolerated - no serious adverse events**
- Multiple studies of mutagenicity (cancer) are clear
- Numerous studies to date indicate the safety of RECCE® 327
- Is suited to administration against sepsis by intravenous drip
- Indicates a safe therapeutic dosing window over multiple time stamps

RECCE® 327 Mechanism of Action




Stage 1

RECCE 327 targets and irreversibly bind to essential bacterial proteins




Stage 2

RECCE 327 disrupts bacterial metabolism and depletes ATP at the cell surface



Stage 3


RECCE 327 kills bacteria rapidly without inducing cell lysis



Stage 4

RECCE 327 is rapidly and irreversibly bactericidal

RECCE® Multiple Anti-Infective Applications



World Health Organisation (WHO) List of Most Threatening Antibiotic-Resistant Bacteria

The WHO published a priority list of 12 antibiotic-resistant bacteria*.

PRIORITY 1: CRITICAL	RECCE® 327
<i>Pseudomonas aeruginosa</i> , carbapenem-resistant	✓ 1
<i>Enterobacteriaceae</i> , carbapenem-resistant, ESBL-producing	✓ 2
<i>Acinetobacter baumannii</i> , carbapenem-resistant	✓ 3
<i>Mycobacterium tuberculosis</i> , rifampicin-resistant	NOT TESTED
PRIORITY 2: HIGH	
<i>Enterococcus faecium</i> , vancomycin-resistant	✓ 4
<i>Staphylococcus aureus</i> , methicillin-resistant	✓ 5
<i>Neisseria gonorrhoeae</i> , cephalosporin-resistant, fluoroquinolone-resistant	✓ 6
<i>Campylobacter spp.</i> , fluoroquinolone-resistant	NOT TESTED
<i>Salmonellae</i> , fluoroquinolone-resistant	NOT TESTED
<i>Shigella spp.</i> , fluoroquinolone-resistant	NOT TESTED
PRIORITY 3: MEDIUM	
<i>Streptococcus pneumoniae</i> , macrolide-resistant	✓ 7
<i>Haemophilus influenzae</i> , ampicillin-resistant	NOT TESTED
Group A <i>Streptococci</i> , macrolide-resistant	✓ 8
Group B <i>Streptococci</i> , penicillin-resistant	✓ 9

- 1 Active *in vitro* against Recce's own superbug of this bacterium
 - 2 Active *in vivo* against a member of this family CRE *E. coli*
 - 3 Active *in vitro* and against superbug variant CRAB
 - 4 Active *in vitro* against a very closely related species, *Enterococcus faecalis*
 - 5 Active both *in vitro* and *in vivo* against MRSA, Methicillin-resistant *S. aureus*
 - 6 Active *in vitro* (superbug not available)
 - 7 Active *in vitro* against related superbug *Klebsiella pneumoniae*
 - 8 Active *in-vitro* against *Streptococcus pyogenes*
 - 9 Active *in-vitro* against a very closely related species, *Streptococcus pyogenes*
- * List as of 2024



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA

FACT SHEET

RECCE PHARMACEUTICALS LTD (ASX:RCE, FSE:R9Q)



An Emerging Global Leader in a New Generation of Anti-Infectives

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is an Australian clinical stage biotech company engaged in the development and commercialisation of a new class of **Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.**

Recce's lead candidate, RECCE® 327 (R327), is a patented, **broad-spectrum synthetic anti-infective being developed in multiple formulations, including intravenous and topical.** It is designed to treat serious bacterial infections, including those caused by drug-resistant **Gram-positive** and **Gram-negative** pathogens.

R327 as a Topical Gel (R327G) is currently advancing through **late-stage clinical development**, with a particular focus on addressing **diabetic foot infections (DFIs)**, a major complication of diabetes and a significant global health burden. Recce is also advancing a broader portfolio of synthetic anti-infectives targeting a range of unmet medical needs across bacterial and viral infections.

The Company's lead clinical program involves a registrational Phase 3 clinical trial of R327G for the treatment of DFIs, conducted in Indonesia. The trial is designed to generate pivotal safety and efficacy data and serves as a potential gateway to broader regulatory and commercial opportunities across the ASEAN market.

The Company also has a Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established *in vitro* models targeting burn wound infections.

Recce's **fully owned, automated manufacturing facility** in Australia supports ongoing clinical development and scale-up. With a **strong global patent portfolio** and a **targeted focus on unmet medical needs in diabetic wound care, Recce is advancing a next-generation anti-infective platform poised for near-term commercialisation and global expansion.**

Corporate Summary

- Proprietary New Class of Anti-Infectives against bacteria and viruses, protected by Composition of Matter Patent.
- **World's Most Clinically Advanced New Class of Anti-Infectives focussed upon the urgent global health threat of antibiotic-resistant superbugs.**
- Multiple Clinical Trials Complete, others underway - **Broad spectrum therapeutic potential for major unmet medical needs of Sepsis/Urosepsis, Burn Wound Infections, ABSSSIs, DFIs and more**
- R327 bactericidal activity against all ESKAPEE pathogens.
- R327 cleared for use under **Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) - Category A**
- **Global recognition by the World Health Organization - inclusion underscores significance of R327** in combating AMR. **R327 uniquely classified as an adenosine triphosphate (ATP) production disruptor**, the only compound under this category **development for priority pathogens**, recognising Recce's efforts to combat antimicrobial resistance.
- **R327 has been awarded Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA under the GAIN Act, providing Fast Track status and 10 years of market exclusivity post-approval.**
- Australian Government awarded **AUD \$54,947,284 (USD \$37,043,433) Advanced Overseas Finding*** across RCE infectious disease portfolio*

BOARD AND MANAGEMENT

Dr John Prendergast	Executive Chairman
James Graham	Managing Director & Chief Executive Officer
Michele Dilizia	Executive Director & Chief Scientific Officer
Dr Justin Ward	Executive Director & Principal Quality Chemist
Dr Alan W Dunton	Chief Medical Advisor & Non-Executive Director
Alistair McKeough	Non-Executive Director
Arthur Kollaras	Head of Manufacturing
Justin Reynolds	CFO (Outsourced - Pitcher Partners Sydney)
Maggie Niewidok	Company Secretary (Outsourced - Kardos Scanlan)

PATENT PORTFOLIO

Patents covering the manufacturing process run until 2029. Granted provisional patents covering additional modes of delivery and anti-viral uses, run until 2037.

Recce Pharmaceuticals Ltd patent portfolio has continued to strengthen with granted patents in key pharmaceutical markets such as USA, Europe, Japan, China and Australia.

FILED	PATENT FAMILY 1	EXPIRY	PATENT FAMILY 2	EXPIRY	PATENT FAMILY 3	EXPIRY
Australia	✓	2028	✓	2037	✓	2037
USA	✓	2029	✓	2037	✓	2037
Europe	✓	2028	✓	2037	✓	2037
Germany	✓	2028	✓	2037	✓	2037
Spain	✓	2028	✓	2037	✓	2037
France	✓	2029	✓	2037	✓	2037
UK	✓	2028	✓	2037	✓	2037
Italy	✓	2028	✓	2037	✓	2037
Sweden	✓	2028	✓	2037	✓	2037
Japan	✓	2028	✓	2037	✓	2037
China	✓	2028	✓	2037	✓	2037
HK	Pending	2028	Pending	2037	✓	2037

Patent Family 1 - Granted

Unique and highly economical manufacturing process

Patent Family 2 - Pending/Granted

Applications (Multi-drug delivery)

Patent Family 3 - Granted

Anti-viral use


Patent Family 4 - Pending/Granted

Process for Preparation of Biologically Active Copolymer

Australia, Israel, Canada - Granted

Other Patent Cooperation Treaty - **pending/allowed**

RECCE® 327 Mechanism of Action



RECCE® Multiple Anti-Infective Applications

Program and Route of Administration	Indications	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Market	
R327 Topical Gel Registrational Trials	Diabetic Foot Infections Phase 3 Indonesia (ASEAN)	[Progress bar from Discovery to Phase III]						<ul style="list-style-type: none"> Approval received from the Indonesian Drug and Food Regulation Authority, Badan POM, to initiate its Registrational Phase 3 clinical trial in Indonesia ABSSSI includes postoperative infection, wound infections and diabetic foot infections
	Acute Bacterial Skin and Skin Structure Infections (DFI) Australia (for US FDA submission)	[Progress bar from Discovery to Phase III]						
R327 Intravenous and Backups	cUTI/Hospital and Ventilator Acquired Pneumonia Other Serious Infections	[Progress bar from Discovery to Phase II]						<ul style="list-style-type: none"> Completed pilot civil Phase II Burn Wound Infections Study; US\$2M grant for Department of Defense pre-clinical pipeline in progress Cooperative Research and Development Agreement signed with US Army Medical Research Institute of Infectious Diseases, to test R327 against biothreat pathogens in established <i>in vitro</i> models.
Aerosol for Inhalation	Hospital Acquired Pneumonia Ventilator-Associated Pneumonia Serious Lung Infections	[Progress bar from Discovery to Phase II]						
Civil and Dept of Defense Programs	Burn Wound Infections	[Progress bar from Discovery to Phase II]						

Efficacy - RECCE® 327

- Achieved a 93% positive clinical response in diabetic foot infection (DFI) patients during Phase II trials, with **no serious adverse events reported**
- Multiple SAS Category A patient cases in Australia have shown **rapid clinical improvement with R327G**, including the avoidance of surgical intervention in severe infections
- In SAS Category A use, R327 demonstrated visible reductions in swelling, redness, and infection progression within 24–72 hours of a single application
- Maintains potency across both Gram-positive and Gram-negative bacteria, including their drug-resistant variants**
- Time-kill studies show R327 acts faster than conventional antibiotics, rapidly depleting bacterial ATP and causing irreversible bacterial death
- Demonstrated 99.9% *in vitro* efficacy against the full suite of ESKAPEE pathogens**

Safety - RECCE® 327

- R327 has been shown to be safe and well tolerated across multiple Phase I and II clinical trials and/or SAS Category A patient cases – as either intravenous or topical gel**
- Phase I trials demonstrated intravenous **safety profile even at high doses up to 6,000 mg** delivered over a one-hour infusion
- No clinically significant changes were observed in laboratory tests, EKGs, telemetry, or vital signs, supporting systemic safety
- R327 displayed a clear therapeutic window across multiple dosing schedules and concentrations
- Topical application has shown to be non-irritating and well tolerated, even in infected, open wound sites**
- Multiple R327 studies of mutagenicity (cancer) are clear**



Sydney – Head Office

Level 15, 1 Farrer Place
Governor Macquarie Tower
Sydney NSW 2000
Australia

Macquarie Park – Production

Unit 8, 64 Talvera Road
Macquarie Park NSW 2113
Australia

Perth – R&D Centre

Suite 10, 3 Brodie Hall Drive
Technology Park
Bentley WA 6102
Australia

North America – Operations

Suite 1025
1717 Pennsylvania Avenue
Washington DC 20006
USA